D.E. Shaw & Co
TTPH

D.E. Shaw & Co’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

D.E. Shaw & Co’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-500
Closed -$474K – 3994
2015
Q2 		$474K Hold
500
– – ﹤0.01% 3190
2015
Q1 		$366K Buy
+500
New +$376K ﹤0.01% 3221

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's TTPH Position: Q4 2018 in Review

D.E. Shaw & Co sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2018, closing a stake of 1,300 shares — an estimated $72K sold.

D.E. Shaw & Co first reported a position in TTPH in Q2 2013 and held it in 14 quarters. The position peaked at $4.05M in Q3 2017. 86 funds tracked by Wall St. Rank hold TTPH as of Q4 2018.

  • D.E. Shaw & Co reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,300 Tetraphase Pharmaceuticals, Inc. shares in Q4 2018, an estimated $72K.
  • D.E. Shaw & Co first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
  • D.E. Shaw & Co's Tetraphase Pharmaceuticals, Inc. position peaked at $4.05M in Q3 2017.
  • 86 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2018.

Based on D.E. Shaw & Co's 13F filing for Q4 2018, filed 14 Feb 2019.